Early and accurate diagnosis is essential for optimal therapeutic outcomes in patients infected with HIV. Currently, none of the commercially available fourth-generation assays differentiate HIV-1 and HIV-2 antibodies (Ab) or the HIV-1 p24 antigen (Ag). The aim of this study was to evaluate the performance of a novel assay, the BioPlex 2200 HIV Ag-Ab. This assay uses a multiplex flow immunoassay design allowing the simultaneous detection and identification of antibodies to HIV-1 (groups M and O), HIV-2, and the HIV-1 p24 antigen, in addition to providing a traditional composite result. A total of 1,505 routine serum samples were prospectively tested. Results were compared with those from the Architect HIV Combo assay. The sensitivity of the BioPlex 2200 was 100%. The specificity assessed on repeated false-positive samples was 99.5%. In addition, 524 frozen specimens from patients known to be infected with HIV-1 or HIV-2 were tested. Of these specimens, 420 were infected with HIV-1, including 156 of known genotypes, 86 were infected with HIV-2, 7 were infected with HIV-1 and HIV-2, and 11 were from patients with acute HIV infection. Sensitivity was 100% for the HIV genotypes tested. The differentiation capabilities of the BioPlex 2200 HIV Ag-Ab assay for HIV-1, HIV-2, dual HIV-1/HIV-2, and early infections were 100%, 90.7%, 100%, and 90.9%, respectively. The BioPlex 2200 is a sensitive and specific assay that offers advantages over conventional HIV combo assays, also referred to as fourth-generation assays, to accurately differentiate and report HIV-1 p24 antigen and HIV-1 and HIV-2 antibodies.
arly diagnosis is essential for optimal outcomes in patients infected with HIV because it facilitates timely initiation of appropriate care, and it decreases the rate of HIV transmission by 3-to 5-fold (1) . The importance of early detection is underlined by studies demonstrating increased life expectancy following early initiation of antiviral treatment. Moreover, several recent highprofile studies have highlighted the potential for limiting viral reservoir expansion and offering protection of innate and specific immunity from the deleterious effects of chronic immune activation by initiating antiretroviral therapy (ART) during acute HIV-1 infection (AHI) (2, 3) . For 30 years, remarkable progress has been made in the development of tools for HIV detection. HIV combo assays, also referred to as fourth-generation assays, detect both HIV-1 and HIV-2 antibodies (Ab) and the HIV-1 p24 antigen (Ag) which reduces, compared to third-generation assays, the window period to an average of 2 weeks (4) (5) (6) (7) (8) (9) (10) (11) (12) .
HIVs display extraordinary genetic diversity due to their fantastic recombination properties. They are subdivided into HIV-1 and -2 and, among HIV-1, 4 groups (M, N, O, and P), of which the pandemic group M includes 9 subtypes and more than 40 circulating recombinant forms (CRFs) as well as numerous unique recombinant forms (URFs). In France, the epidemic in recent years has been characterized by the predominance of subtype B strains but with increases of non-B subtypes (around 50%).
Although the sensitivities and specificities of screening assays have improved, the genetic variability of HIV still represents a challenge, in particular for early detection of infection. For example, a correct serological diagnosis of HIV-2 infection may be missed. The use of HIV-1 Western blot assay as the sole confirmatory test in areas where HIV-2 is not endemic may in fact lead to misclassification of HIV-2-infected individuals as HIV-1 positive. This is due to cross-reactivity between HIV-2 antibodies and envelope glycoproteins of HIV-1. The precise detection of HIV-2 has implications for the choice of antiretroviral treatment (13) . Indeed, HIV-2 strains are naturally resistant to nonnucleoside reverse transcriptase inhibitors (NNRTI) and fusion inhibitors and are less sensitive in vitro to some protease inhibitors (14, 15) .
Another challenge is posed by HIV-O strains, which are highly divergent from the major group M, leading to their designation as outliers. These strains also display marked intragroup genetic diversity (16) . This genetic diversity has important implications for diagnosis and monitoring of HIV-O infection, including risks of false negativity and viral load underestimations (17) (18) (19) .
New assays allowing the detection and differentiation of HIV-1 (group M and O) and HIV-2 are necessary to improve the diagnosis of HIV infection. Currently, none of the commercially available fourth-generation assays have this capability. The BioPlex 2200 HIV Ag-Ab uses a multiplex flow immunoassay design that permits simultaneous detection, identification, and reporting of antibodies to HIV-1 (groups M and O) and HIV-2 and the HIV-1 p24 antigen in a single reaction vessel.
The aim of this study was to evaluate the sensitivity and specificity of the BioPlex 2200 HIV Ag-Ab assay and its ability to detect and differentiate acute HIV infection (AHI) and HIV-1 and HIV-2 infections.
MATERIALS AND METHODS
Patient samples. Patient samples were from two populations. The first population consisted of 1,505 fresh specimens obtained during a prospective study between October 2012 and February 2013 from hospitalized patients (Saint-Louis Hospital, Paris, France) for whom screening for HIV infection was requested. The second population included 524 frozen specimens from patients known to be infected by HIV-1 or HIV-2. Of these specimens, 420 were from individuals infected by HIV-1, and 156 of the specimens were of known genotype, including 8 HIV-1 group O samples. There were 86 HIV-2 samples, 7 samples from individuals infected by both HIV-1 and HIV-2, and 11 samples from patients with acute HIV-1 infection (AHI). The study was carried out in accordance with the Declaration of Helsinki. This study was a noninterventional study with no addition to usual procedures. Biological material and clinical data were obtained only for routine viral diagnostic testing according to physicians' directions (no specific sampling and no modification of the sampling protocol). Data analyses were carried out using an anonymized database. The BioPlex 2200 HIV Ag-Ab assay was designed to have an analytical sensitivity of Ͻ12.5 pg/ml for HIV-1 p24 antigen on a panel derived from the National Agency for the Safety of Medicines and Health Products (MSNA) and Ͻ2 IU/ml on the WHO HIV international standard NIBSC 60/636. Results for antigen sensitivity are 7.02 pg/ml (range, 6.82 to 7.22 pg/ml) on the MSNA standard and 0.637 IU/ml (range, 0.615 to 0.658 IU/ml) on the WHO standard (BioPlex 2200 HIV Ag-Ab; Bio-Rad Laboratories, Hercules, CA).
(ii) Architect HIV Combo assay. The Architect HIV Combo assay is a chemiluminescent magnetic microparticle-based immunoassay run on an automated random access instrument. Briefly, the assay is designed to give a single, confounded result based on detection of HIV type 1 antibodies (HIV-1 Final classification was established using predicate assays following a test algorithm (Fig. 1) . To calculate sensitivity and specificity, specimens were considered to be HIV infected if they were repeatedly reactive by the Architect HIV Ag/Ab Combo assay and reactive by a Western blotting test or if HIV-1 or -2 RNA was detected. They were considered to be AHI if the serology results were indeterminate (using Architect or Western blot) and HIV-1 or -2 RNA was detected. Samples that were discordant on the BioPlex 2200 for final classification were repeated in duplicate after centrifugation.
The BioPlex 2200 HIV Ag-Ab assay (Bio-Rad, Marnes-la-Coquette) results were compared to the Abbott Architect HIV Combo assay results and to final classification results based on additional testing. The sensitivity analysis included HIV-positive samples only, collected during both prospective and retrospective studies. The specificity analysis included only hospitalized patient samples collected during the prospective study.
RESULTS
During the prospective study in March 2013, a total of 1,505 consecutive specimens were tested using the BioPlex 2200 assay, of which 35 were considered HIV infected, based on Architect reactivity and confirmation test results. During the screening, the BioPlex 2200 correctly identified these 35 positive specimens, giving a sensitivity of 100% (95% confidence interval [CI], 96.7 to 100), and 1,461 negative specimens, giving a specificity of 99.4% (95% CI, 99 to 99.8). There were 9 false positives on initial screening. Out of the 9 specimens, repeat testing with the BioPlex 2200 assay reported 1 negative result and 8 repeatedly reactive results, leading to a specificity of 99.5% (95% CI, 99.1 to 99.9%) ( Table 1 ).
In the retrospective study, a total of 420 HIV-1-positive specimens, 11 AHI specimens (HIV-1), 86 HIV-2-positive specimens, and 7 HIV-1 and HIV-2 specimens from co-infected patients were tested using the BioPlex 2200 assay. All these specimens were reactive on the BioPlex 2200 ( Table 2) .
The 420 specimens from HIV-1-infected-patients tested reactive on the BioPlex 2200 HIV Ag-Ab, with only HIV-1 Ab reactivity. At least 28 different genotypes were represented, and the sensitivity was 100% (95% CI, 99.3 to 100) ( Table 3 ). All specimens were correctly classified as HIV-1 reactive by the BioPlex 2200, indicating a differentiation capability of 100% (95% CI, 99.3 to 100). The BioPlex 2200 assay's sensitivity was unaffected by the HIV-1 group or subtype. Eight HIV-1 group O samples were classified as HIV-1. All of the 11 AHI HIV-1 specimens tested reactive on the BioPlex 2200. Five of them were reactive with both HIV-1 Ab and HIV-1 p24 Ag, two with only HIV-1 p24 Ag, two with only HIV-1 Ab, and one with an HIV undifferentiated result.
All of the 86 specimens considered HIV-2 infected tested reactive on the BioPlex 2200, with 78 specimens giving an HIV-2 Abreactive result, and 8 giving an HIV-undifferentiated result. These results gave a sensitivity for HIV-2-positive specimens of 100% (95% CI, 96.6 to 100) and an HIV-1/2 differentiation capability of 90.7% (95% CI, 82.5 to 95.9).
All of the specimens positive for both HIV-1 and HIV-2 tested reactive on the BioPlex 2200, with HIV-undifferentiated results giving a sensitivity of 100% for these specimens.
DISCUSSION
The results of this study show that the BioPlex 2200 is highly sensitive and specific in clinical sample populations and has performance comparable to that of the Architect HIV Combo assay. In contrast to the alternative assays, the BioPlex 2200 assay offers the advantage of calculating and reporting separate values for HIV-1 p24 Ag and HIV-1 (group M and O) and HIV-2 antibodies. Currently, to our knowledge, no other commercial screening assay can differentiate HIV-1 (group M and O) and HIV-2. Individual reporting of HIV-1 group M and O results are for research use only (RUO) since the BioPlex 2200 will not report results for the two bead populations separately.
The detection of AHI has been shown to be beneficial for the prompt initiation of appropriate antiretroviral therapy. In fact, HIV primary infections are now considered a therapeutic emergency to limit, by early and adapted highly active antiretroviral therapy (HAART), the viral reservoir constitution. In this way, the BioPlex 2200 is an interesting test because it allows differentiation between HIV-1 p24 antigen and HIV antibody reactivity. During this study, the BioPlex 2200 showed excellent sensitivity for the detection of AHI by detecting HIV-1 p24 antigen reactivity in 7 of the 11 AHI samples.
Because of the growing number of people with HIV-1 group M non-B-subtype infections, it is essential that HIV assays detect infection independently of subtype. Studies have demonstrated that some fourth-generation HIV assays do not detect certain HIV-1 group M, non-B subtypes, yielding false-negative results (8, 21) . The BioPlex 2200 HIV Ag-Ab assay had 100% sensitivity for all of the HIV-1 groups (M and O) and subtypes (n Ͼ 20) tested and for HIV-2. Various HIV-1 subtypes tested in our study were represented as major recombinant forms and very divergent strains currently observed in Africa, Europe, and elsewhere.
Two samples from individuals infected by HIV-1 group O tested positive on the BioPlex 2200 with HIV-O antibody reactivity with no cross-reactivity with the group M antigen target. This shows the importance of including BioPlex 2200 HIV Ag-Ab beads with the HIV-1 group O-specific epitope. This observation suggests that it may be possible for specialists to observe, under RUO conditions, specific binding reactivity to characterized samples suspected of being group O positive.
The BioPlex 2200 HIV Ag-Ab assay identifies patients infected by HIV-1 or HIV-2 and has excellent specificity to discriminate between two HIV infections, allowing early initiation of adapted antiretroviral treatment and avoiding inappropriate therapy in HIV-2 patients with natural resistance to NNRTI.
It is conventional to classify the HIV screening enzyme immunoassays (EIAs) according to their technological advancement. So we went past the first generation to the fourth generation according to the nature of the antigens, the EIA detection formats, and the detection of p24 antigen. The shift to a test using a sandwich method with detection and differentiation by the Luminex technology allows us to consider this new tool a new generation of test.
This study shows that the next-generation BioPlex 2200 HIV Ag-Ab assay performs well in the diagnosis of HIV infection, with excellent sensitivity and specificity. In conclusion, the BioPlex 2200 could be an alternative to fourth-generation assays by allowing screening for early infection for rapid HAART initiation and simultaneous differentiation of HIV-1 and HIV-2.
